Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AB

WKN: A3D38R | ISIN: US0547548588 | Ticker: AY20
Lang & Schwarz
17.11.26 | 07:00
1,900 Euro
-100,00 % -1,900
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AYTU BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
AYTU BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9001,90017.11.

Aktuelle News zur AYTU BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAytu BioPharma Stock Climbs 44% After-Hours: Here's Why2
MoRosemont to acquire Aytu BioPharma for $2.70 per share17
MoAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results366Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / ACCESS Newswire / November...
► Artikel lesen
AYTU BIOPHARMA Aktie jetzt für 0€ handeln
MoAytu BioPharma GAAP EPS of -$0.20 beats by $0.14, revenue of $14.84M beats by $1.57M5
MoRosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion403Agreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share.Proposed acquisition brings an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset...
► Artikel lesen
MoAytu BioPharma, Inc.: Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer404Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per shareTender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to...
► Artikel lesen
FrAytu BioPharma Q3 2027 Earnings Preview1
10.11.Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026258DENVER, CO / ACCESS Newswire / November 10, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
► Artikel lesen
24.09.Aytu BioPharma Reports $16.1 Million In Fourth-Quarter Revenue As EXXUA Sales Reach $3.9 Million2
23.09.Aytu outlines $49M-$54M FY27 operating expense plan as it targets 66%-67% gross margin in Q4 FY272
22.09.Earnings Call Transkript: Aytu BioPharma übertrifft Umsatzprognose für Q4 20261
22.09.Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call3
22.09.AYTU BIOPHARMA, INC - 10-K, Annual Report1
22.09.Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results617Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6...
► Artikel lesen
22.09.AYTU BIOPHARMA, INC - 8-K, Current Report2
21.09.Aytu BioPharma Q4 2026 Earnings Preview1
16.09.Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026403DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
► Artikel lesen
25.06.AYTU BIOPHARMA, INC - 8-K, Current Report2
01.06.Aytu BioPharma, Inc.: Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026431DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous...
► Artikel lesen
18.05.Aytu BioPharma, Inc.: Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026540DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous...
► Artikel lesen
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1